Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.

Liu, Xiaoyan; Lang, Yitian; Liao, Yahui; Zhu, Yizhun

Liu, Xiaoyan; Lang, Yitian; Liao, Yahui; Zhu, Yizhun.

Afiliación

Liu X; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lang Y; State Key Laboratory of Quality Research in Chinese Medicine, School of Pharmacy, Macau University of Science and Technology, Taipa, Macau SAR, China.
Liao Y; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhu Y; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Front Public Health ; 9: 756899, 2021.

Article en En | MEDLINE | ID: mdl-34778188

Asunto(s)

Neoplasias de la Mama Triple Negativas; Anticuerpos Monoclonales Humanizados/uso terapéutico; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Análisis Costo-Beneficio; Humanos; Neoplasias de la Mama Triple Negativas/tratamiento farmacológico

Palabras clave

atezolizumab; cost-effectiveness; partitioned survival model; the perspective of China; triple-negative breast cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas Tipo de estudio: Health_economic_evaluation Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Front Public Health Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google